Breaking News

UPM, Amerigen Enter Long-Term Mfg. Pact

April 3, 2014

Will supply two ANDA products under a 10-year commercial agreement

UPM, a division of Gregory Pharmaceutical Holdings, Inc., has entered an agreement with Amerigen Pharmaceuticals, Inc. to manufacture two ANDA products for a 10- year commercial supply term. Also, UPM may potentially develop and supply several additional ANDA products for Amerigen under the agreement.
 
Back in July 2013, UPM acquired Pfizer’s 475,000 sq.-ft. manufacturing facility in Bristol, TN, which is where all of these products will eventually be made.
 
Dr. John M. Gregory, chairman and chief executive officer of Gregory Pharmaceutical Holdings, Inc., said, "UPM has been working with Amerigen for the past three years. We have a strong working relationship with their company and are impressed with their technical team and their business development approach. We believe this agreement cements our partnership with Amerigen. Also, it is another example of UPM's transition from a company that formerly focused on only early stage development, but now, provides a full range of solid dose commercial services for our clients."
 
Jonathan Embleton, chief business officer of Amerigen, said, "Amerigen looks forward to a long relationship with UPM.  We are excited about our upcoming product portfolio and the role UPM will play in providing products to market."

Related Packaging:

Related Contract Manufacturing:

Related Compliance:

blog comments powered by Disqus
  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Continuous Pharmaceutical Processes and Their Demands

    Continuous Pharmaceutical Processes and Their Demands

    Girish Malhotra, EPCOT International||April 5, 2016
    A look at the unique characteristics of continuous processes in pharmaceutical manufacturing.

  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?